Defunct Company
Total Trials
7
As Lead Sponsor
6
As Collaborator
1
Total Enrollment
922
NCT05364021
Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies
Phase: Phase 1/2
Role: Lead Sponsor
Start: Mar 3, 2022
Completion: Nov 20, 2023
NCT05626634
Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy
Phase: Phase 2
Start: Nov 8, 2022
Completion: Dec 20, 2024
NCT05834569
Impact of Maxigesic on Delirium After Minimally Invasive Lung Surgery in Elderly Patients
Phase: Phase 4
Role: Collaborator
Start: Jun 15, 2023
Completion: Jan 23, 2025
NCT06660394
A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
Phase: Phase 3
Start: Sep 25, 2024
Completion: Oct 2, 2026
NCT06719141
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)
Start: Nov 11, 2024
Completion: Nov 30, 2026
NCT06908226
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)
Start: Feb 12, 2025
Completion: Dec 31, 2027